Shares of Neuland Laboratories, a pharmaceutical company, surged by 7.65% to reach an intraday high of ₹18,305 following a remarkable Q4 FY26 performance. The company reported a 660% increase in consolidated net profit, amounting to ₹213 crore, compared to ₹28 crore in the same quarter last year. Revenue also saw significant growth, more than doubling with a 136% rise to ₹776.3 crore from ₹328.4 crore in Q4 FY25. The strong operating performance is highlighted by an EBITDA increase to ₹319 crore, up from ₹58 crore a year ago, indicating enhanced operational efficiency and margin expansion. CEO Saharsh Davuluri expressed confidence in the company's future, noting a focus on execution discipline and strategic investments in peptide manufacturing and a new R&D center. Over the past month, Neuland's shares have gained nearly 20%, and the stock has increased approximately 572% over the last three years, with a current market capitalization of around ₹22,366 crore.